ClinicalTrials.gg
CompletedNCT05028582ARRECTORUpdated Jul 17, 2025Results posted

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

A Phase 3 interventional study of Roflumilast Foam 0.3% and Vehicle Foam in Scalp Psoriasis, sponsored by Arcutis Biotherapeutics, Inc.. Completed at 49 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.

Sponsored by Arcutis Biotherapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
432
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Psoriasis · Arcutis Biotherapeutics, Inc..

Enrollment
3rd of 12
432 · median 318
Started
2021
with 1 other
Phase 3
4 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc., this one is the 3rd largest by enrollment, is one of 2 that started in 2021, is one of 4 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Psoriasis by Arcutis Biotherapeutics, Inc. as a file.
02

Study summary

This was a parallel group, double blind, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-154) 0.3% foam vs vehicle foam applied once daily (qd) for 8 weeks by participants with plaque psoriasis of the scalp and body.

03

Conditions studied

  • Scalp Psoriasis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For adult subjects: Participants legally competent to read, write, and sign and give . For adolescent subjects: Informed consent of a parent(s) or legal guardian, and assent by the subjects, as required by local laws.
  • Males and females ages 12 years and older (inclusive) at the time of consent or assent.
  • Scalp psoriasis with a Scalp-Investigator Global Assessment of Disease (S IGA) severity of at least Moderate ('3') at Baseline.
  • Extent of scalp psoriasis involving ≥ 10% of the total scalp at Baseline.
  • A Psoriasis Scalp Severity Index (PSSI) of at least 6 at Baseline.
  • An IGA of body (i.e., non-scalp) psoriasis (B-IGA) of at least Mild ('2') at Baseline.
  • A PASI score of at least 2 (excluding palms and soles) at Baseline.
  • Clinical diagnosis of psoriasis vulgaris of at least 6 months duration at Screening as determined by the Investigator. Stable disease for the past 4 weeks.
  • Total overall psoriasis involvement on scalp and non-scalp areas ≤ 25% BSA (not including palms/soles) at Baseline. Total non-scalp BSA should not exceed 20%.
  • Female subject of (FOCBP) must have a negative serum pregnancy test at Screening (Visit 1) and negative urine pregnancy test at Baseline (Visit 2). In addition, sexually active FOCBP must agree to use at least one form of highly effective or a barrier method of contraception throughout the study according to Contraception Requirements for the protocol.
  • Females of non-childbearing potential must either be premenarchal, with spontaneous amenorrhea for at least 12 months (post-menopausal status will be confirmed with FSH testing) or have undergone surgical sterilization according to Contraception Requirements for the protocol. Prepubescent females must agree to be abstinent during the study.
  • Subjects in good health as judged by the Investigator, based on medical history, physical examination, vital signs, serum chemistry labs, hematology values, and urinalysis.

Exclusion criteria

Exclusion Criteria:

  • Subjects who cannot discontinue treatment with therapies for the treatment of psoriasis vulgaris prior to the Baseline visit and during the study.
  • Planned excessive exposure to treated area(s) to either natural or artificial sunlight, tanning bed, or other LED.
  • Previous treatment with ARQ-151 or ARQ-154.
  • Females who are pregnant, wishing to become pregnant during the study, or are breast feeding.
  • Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
  • Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members residing in the same household of enrolled subjects.
  • Any condition that in the Investigator's assessment would preclude the subject from participating in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
432 participants (actual)

Study arms

  • Active comparator
    Roflumilast Foam 0.3%

    Participants with plaque psoriasis of the scalp and body applied roflumilast foam 0.3% once daily (qd) for 8 weeks.

    Drug: Roflumilast Foam 0.3%

  • Placebo comparator
    Vehicle Foam

    Participants with plaque psoriasis of the scalp and body applied vehicle foam qd for 8 weeks.

    Drug: Vehicle Foam

Interventions

  • DrugRoflumilast Foam 0.3%

    Roflumilast foam 0.3%

    Also known as: ARQ-154 0.3%

  • DrugVehicle Foam

    Vehicle foam matched to roflumilast 0.3% foam.

06

What researchers measure

Primary outcomes

  1. Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8

    The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

    Time frame: Week 8

  2. Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8

    The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

    Time frame: Week 8

Secondary outcomes

  1. Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2

    The percentage of participants with SI-NRS success at Week 2 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

    Time frame: Week 2

  2. Achievement of SI-NRS Success at Week 4

    The percentage of participants with SI-NRS success at Week 4 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

    Time frame: Week 4

  3. Achievement of SI-NRS Success at Week 8

    The percentage of participants with SI-NRS success at Week 8 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

    Time frame: Week 8

  4. Change From Baseline in SI-NRS Score at Day 1

    SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

    Time frame: Day 1

  5. Change From Baseline in SI-NRS Score at Day 3

    SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

    Time frame: Day 3

  6. Change From Baseline in SI-NRS Score at Week 1

    SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

    Time frame: Week 1

  7. Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8

    WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from 0 ("no itch") to 10 ("worst imaginable itch"). Success is defined as achievement of a ≥ 4-point improvement from baseline in participants with a baseline WI-NRS pruritus score of ≥ 4.

    Time frame: Week 8

  8. Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.

    Time frame: Week 8

  9. Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The aggregate Itching, Pain, and Scaling score ranges from 0 to 30; the change from baseline in aggregate score was assessed per protocol only in adult participants.

    Time frame: Week 8

  10. Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.

    Time frame: Week 8

  11. Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Pain score ranges from 0 to 10.

    Time frame: Week 8

  12. Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8

    The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.

    Time frame: Week 8

  13. Percentage of Participants Achieving PSD Total Score of 0 at Week 8

    Time frame: Week 8

  14. Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)

    The PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).

    Time frame: Week 8

  15. Achievement of S-IGA Score of 'Clear' at Week 8

    The percentage of participants with S-IGA score of 0 Week 8 is presented. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

    Time frame: Week 8

  16. Achievement of S-IGA Success at Week 2

    The percentage of participants with S-IGA success at Week 2 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

    Time frame: Week 2

  17. Achievement of S-IGA Success at Week 4

    The percentage of participants with S-IGA success at Week 4 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

    Time frame: Week 4

  18. Change From Baseline in PASI Score at Week 2

    The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.

    Time frame: Week 2

07

Results

Posted Jul 17, 2025

Participant flow

Participant flow — Overall Study
MilestoneRoflumilast Foam 0.3%Vehicle Foam
Started281151
Completed250126
Not completed3125
Withdrew: Lost to follow-up119
Withdrew: Withdrawal by subject910
Withdrew: Adverse event52
Withdrew: Miscellaneous32
Withdrew: Lack of efficacy31
Withdrew: Physician decision01

Outcome measures

PrimaryAchievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8

The percentage of participants with S-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 866.4 (59.62 to 72.56)27.8 (20.12 to 37.10)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio, log: 5.19 · 97.5% CI 2.90 to 9.31Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
PrimaryAchievement of Body Investigator Global Assessment (B-IGA) Success at Week 8

The percentage of participants with B-IGA success at Week 8 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline at Week 8. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2),Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Body Investigator Global Assessment (B-IGA) Success at Week 845.5 (38.87 to 52.33)20.1 (13.55 to 28.81)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.17 · 97.5% CI 1.75 to 5.73Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryAchievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2

The percentage of participants with SI-NRS success at Week 2 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 2
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of Scalp Itch-Numeric Rating Score (SI-NRS ) Success at Week 225.2 (18.96 to 32.63)8.0 (3.90 to 15.55)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0005 · Odds ratio (or): 4.67 · 97.5% CI 1.60 to 13.62Stratified by pooled study site, baseline S IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryAchievement of SI-NRS Success at Week 4

The percentage of participants with SI-NRS success at Week 4 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of SI-NRS Success at Week 4
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of SI-NRS Success at Week 446.2 (38.32 to 54.22)16.8 (10.40 to 26.04)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.39 · 97.5% CI 2.01 to 9.55Stratified by pooled study site, baseline S IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryAchievement of SI-NRS Success at Week 8

The percentage of participants with SI-NRS success at Week 8 is presented. Success is defined as a ≥ 4-point improvement from baseline weekly in weekly average SI-NRS in participants with weekly average baseline SI-NRS score ≥4. SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of SI-NRS Success at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of SI-NRS Success at Week 865.3 (57.26 to 72.58)30.3 (21.38 to 40.91)
Statistical analysis
  • Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.41 · 97.5% CI 2.49 to 11.78Stratified by pooled study site, baseline S IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryChange From Baseline in SI-NRS Score at Day 1

SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

Time frame:
Day 1
Reported as:
Least squares mean · score on a scale
Change From Baseline in SI-NRS Score at Day 1
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Change From Baseline in SI-NRS Score at Day 1-0.44 ± 0.120-0.09 ± 0.149
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = 0.0164 · Ls mean difference: -0.35 · 97.5% CI -0.68 to -0.02ANCOVA terms of treatment, pooled study site, baseline S-IGA, baseline B-IGA, and baseline SI-NRS score
SecondaryChange From Baseline in SI-NRS Score at Day 3

SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

Time frame:
Day 3
Reported as:
Least squares mean · score on a scale
Change From Baseline in SI-NRS Score at Day 3
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Change From Baseline in SI-NRS Score at Day 3-1.11 ± 0.133-0.36 ± 0.165
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = <0.0001 · Ls mean difference: -0.76 · 97.5% CI -1.12 to -0.39ANCOVA terms of treatment, pooled study site, baseline S-IGA, baseline B-IGA, and baseline SI-NRS score
SecondaryChange From Baseline in SI-NRS Score at Week 1

SI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale ranges from 0 ("no itch") to 10 ("worst imaginable itch"), with higher scores indicative of greater symptom severity. A negative change from baseline indicates symptom improvement, and vice versa.

Time frame:
Week 1
Reported as:
Least squares mean · score on a scale
Change From Baseline in SI-NRS Score at Week 1
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Change From Baseline in SI-NRS Score at Week 1-1.08 ± 0.121-0.53 ± 0.151
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = 0.0002 · Ls mean difference: -0.55 · 97.5% CI -0.87 to -0.22ANCOVA terms of treatment, pooled study site, baseline S-IGA, baseline B-IGA, and baseline SI-NRS score
SecondaryAchievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8

WI-NRS is a subject-reported severity of itch at its highest intensity during the previous 24-hour period. The scale is from 0 ("no itch") to 10 ("worst imaginable itch"). Success is defined as achievement of a ≥ 4-point improvement from baseline in participants with a baseline WI-NRS pruritus score of ≥ 4.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of WI-NRS (Worst Itch-Numeric Rating Score) Success at Week 863.1 (54.97 to 70.59)30.1 (20.69 to 41.44)
Statistical analysis
  • Roflumilast Foam 0.3% · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.14 · 97.5% CI 2.01 to 8.52Stratified by pooled study site, baseline S-IGA, and baseline B-IGA
SecondaryAchievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of a 75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75)50.1 (43.24 to 56.91)16.8 (10.77 to 25.15)
Statistical analysis
  • Roflumilast Foam 0.3% · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.42 · 97.5% CI 2.73 to 10.75Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryChange From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The aggregate Itching, Pain, and Scaling score ranges from 0 to 30; the change from baseline in aggregate score was assessed per protocol only in adult participants.

Time frame:
Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Change From Baseline in Psoriasis Symptoms Diary (PSD) Aggregate Score of Itching, Pain, and Scaling (Questions 1, 9, and 11)-10.87 ± 0.546-5.75 ± 0.698
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = <0.0001 · Ls mean difference: -5.12 · 97.5% CI -6.64 to -3.60Covariate terms of treatment, pooled study site, baseline S-IGA, baseline B-IGA and baseline PSD aggregate score \& multiple imputation of missing data
SecondaryPercentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Percentage of Participants Achieving PSD Itching (Question 1) Score of 0 at Week 831.7 (25.63 to 38.58)10.0 (5.55 to 17.32)
Statistical analysis
  • Roflumilast Foam 0.3% · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.59 · 97.5% CI 2.10 to 10.04Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryPercentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Pain score ranges from 0 to 10.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Percentage of Participants Achieving PSD Pain (Question 9) Score of 0 at Week 864.9 (58.03 to 71.24)40.3 (31.36 to 49.95)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 3.23 · 97.5% CI 1.83 to 5.68Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryPercentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8

The PSD is a 16-item questionnaire asking subjects to rate the severity of psoriasis-related symptoms in the past 24 hours. Each question is scored from 0 ("no symptoms") to 10 ("worst imaginable symptoms"). Scores range from 0 to 160, with higher scores indicating greater symptom severity. The Scaling score ranges from 0 to 10.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Percentage of Participants Achieving PSD Scaling (Question 11) Score of 0 at Week 841.5 (34.86 to 48.54)13.6 (8.26 to 21.59)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.56 · 97.5% CI 2.28 to 9.08Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryPercentage of Participants Achieving PSD Total Score of 0 at Week 8
Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PSD Total Score of 0 at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Percentage of Participants Achieving PSD Total Score of 0 at Week 819.6 (14.65 to 25.82)7.1 (3.50 to 13.79)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.0012 · Odds ratio (or): 3.27 · 97.5% CI 1.39 to 7.68Stratified by pooled study site, baseline S-IGA, and baseline B-IGA
SecondaryAchievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)

The PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease). PSSI combines the assessment of the severity of scalp lesions and the area of scalp affected into a single score in the range 0 (no disease) to 72 (maximal disease).

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of a 75% Reduction From Baseline in Psoriasis Scalp Severity Index (PSSI) Score (PSSI-75)70.9 (64.27 to 76.70)31.3 (23.15 to 40.72)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 5.40 · 97.5% CI 2.98 to 9.77Stratified by pooled study site, baseline S IGA, and baseline B IGA with multiple imputation to handle missing data
SecondaryAchievement of S-IGA Score of 'Clear' at Week 8

The percentage of participants with S-IGA score of 0 Week 8 is presented. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Achievement of S-IGA Score of 'Clear' at Week 8
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of S-IGA Score of 'Clear' at Week 840.0 (33.47 to 46.81)9.1 (4.88 to 16.18)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 6.77 · 97.5% CI 3.04 to 15.05Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryAchievement of S-IGA Success at Week 2

The percentage of participants with S-IGA success at Week 2 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Time frame:
Week 2
Reported as:
Number · percentage of participants
Achievement of S-IGA Success at Week 2
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of S-IGA Success at Week 230.4 (24.62 to 36.92)11.7 (6.90 to 19.20)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.10 · 97.5% CI 1.84 to 9.13Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryAchievement of S-IGA Success at Week 4

The percentage of participants with S-IGA success at Week 4 is presented. Success is defined as an IGA score of 'clear' or 'almost clear' plus a 2-point improvement from baseline. This global assessment scale has five severity grades reported from 0-4 and defined as Clear (0), Almost Clear (1), Mild (2), Moderate (3), Severe (4), with higher scores indicative of greater symptom severity.

Time frame:
Week 4
Reported as:
Number · percentage of participants
Achievement of S-IGA Success at Week 4
percentage of participantsRoflumilast Foam 0.3%Vehicle Foam
Achievement of S-IGA Success at Week 453.8 (47.00 to 60.46)19.5 (13.09 to 27.95)
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 4.82 · 97.5% CI 2.62 to 8.84Stratified by pooled study site, baseline S-IGA, and baseline B-IGA with multiple imputation to handle missing data
SecondaryChange From Baseline in PASI Score at Week 2

The Psoriasis Area and Severity Index (PASI) is widely used for the measurement of severity of psoriasis. PASI combines the assessment of the severity of lesions and the area affected into a single score in the range from 0 (no disease) to 72 (maximal disease), with higher scores indicating greater symptom severity. A decrease from baseline indicates symptom improvement, and vice versa.

Time frame:
Week 2
Reported as:
Least squares mean · score on a scale
Change From Baseline in PASI Score at Week 2
score on a scaleRoflumilast Foam 0.3%Vehicle Foam
Change From Baseline in PASI Score at Week 2-2.31 ± 0.157-1.03 ± 0.193
Statistical analysis
  • Roflumilast Foam 0.3% vs Vehicle Foam · ANCOVA · p = <0.0001 · Ls mean difference: -1.28 · 97.5% CI -1.71 to -0.85Covariate terms of treatment, pooled study site, baseline S-IGA, baseline B-IGA, and baseline PASI score \& multiple imputation to handle missing data

Adverse events

Collected over Up to ~12 weeks (8 weeks of treatment + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast Foam 0.3%0/281 (0%)2/281 (0.7%)0/281 (0%)
Vehicle Foam0/151 (0%)1/151 (0.7%)0/151 (0%)
Most frequent serious events
Most frequent serious events
EventRoflumilast Foam 0.3%Vehicle Foam
Radius fractureInjury, poisoning and procedural complications0/2811/151
Joint dislocationInjury, poisoning and procedural complications0/2811/151
Peripheral artery occlusionVascular disorders0/2811/151
Bipolar disorderPsychiatric disorders1/2810/151
GastritisGastrointestinal disorders1/2810/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)Roflumilast Foam 0.3%Vehicle FoamTotal
Mean48.6 ± 14.9345.0 ± 14.3347.3 ± 14.81
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Female15291243
Male12960189
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
Hispanic or Latino482876
Not Hispanic or Latino224121345
Unknown or Not Reported9211
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Roflumilast Foam 0.3%Vehicle FoamTotal
American-Indian or Alaska Native033
Asian26430
Black or African-American12618
Native Hawaiian or Other Pacific Islander314
White225129354
Other11718
More than One Race415
08

Study locations

49 sites
  • Arcutis Biotherapeutics Clinical Site 01
    Scottsdale, Arizona 85255, United States
  • Arcutis Biotherapeutics Clinical Site 50
    Beverly Hills, California 90212, United States
  • Arcutis Biotherapeutics Clinical Site 45
    Encinitas, California 92024, United States
  • Arcutis Biotherapeutics Clinical Site 64
    San Diego, California 92123, United States
  • Arcutis Biotherapeutics Clinical Site 72
    Santa Ana, California 92701, United States
  • Arcutis Biotherapeutics Clinical Site 21
    Santa Monica, California 90404, United States
  • Arcutis Biotherapeutics Clinical Site 33
    Clearwater, Florida 33756, United States
  • Arcutis Biotherapeutics Clinical Site 42
    Coral Gables, Florida 33134, United States
  • Arcutis Biotherapeutics Clinical Site 57
    Delray Beach, Florida 33484, United States
  • Arcutis Biotherapeutics Clinical Site 31
    North Miami Beach, Florida 33162, United States
  • Arcutis Biotherapeutics Clinical Site 05
    Orlando, Florida 32819, United States
  • Arcutis Biotherapeutics Clinical Site 65
    Sanford, Florida 32771, United States
  • Arcutis Biotherapeutics Clinical Site 12
    Tampa, Florida 33613, United States
  • Arcutis Biotherapeutics Clinical Site 22
    Plainfield, Illinois 46168, United States
  • Arcutis Biotherapeutics Clinical Site 10
    Rolling Meadows, Illinois 60008, United States
  • Arcutis Biotherapeutics Clinical Site 15
    Louisville, Kentucky 40217, United States
  • Arcutis Biotherapeutics Clinical Site 04
    Lake Charles, Louisiana 70605, United States
  • Arcutis Biotherapeutics Clinical Site 02
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 28
    Rockville, Maryland 20850, United States
  • Arcutis Biotherapeutics Clinical Site 20
    Detroit, Michigan 48202, United States
  • Arcutis Biotherapeutics Clinical Site 14
    New Brighton, Minnesota 55112, United States
  • Arcutis Biotherapeutics Clinical Site 44
    Saint Joseph, Missouri 64506, United States
  • Arcutis Biotherapeutics Clinical Site 34
    East Windsor, New Jersey 08520, United States
  • Arcutis Biotherapeutics Clinical Site 51
    Rochester, New York 14623, United States
  • Arcutis Biotherapeutics Clinical Site 63
    The Bronx, New York 10462, United States
  • Arcutis Biotherapeutics Clinical Site 23
    High Point, North Carolina 27262, United States
  • Arcutis Biotherapeutics Clinical Site 25
    Portland, Oregon 97223, United States
  • Arcutis Biotherapeutics Clinical Site 27
    Pittsburgh, Pennsylvania 15213, United States
  • Arcutis Biotherapeutics Clinical Site 06
    Knoxville, Tennessee 37922, United States
  • Arcutis Biotherapeutics Clinical Site 13
    Arlington, Texas 76011, United States
  • Arcutis Biotherapeutics Clinical Site 11
    Austin, Texas 78759, United States
  • Arcutis Biotherapeutics Clinical Site 41
    College Station, Texas 77845, United States
  • Arcutis Biotherapeutics Clinical Site 54
    San Antonio, Texas 78213, United States
  • Arcutis Biotherapeutics Clinical Site 24
    San Antonio, Texas 78218, United States
  • Arcutis Biotherapeutics Clinical Site 07
    West Jordan, Utah 84088, United States
  • Arcutis Biotherapeutics Clinical Site 17
    Norfolk, Virginia 23502, United States
  • Arcutis Biotherapeutics Clinical Site 35
    Calgary, Alberta T2J 7E1, Canada
  • Arcutis Biotherapeutics Clinical Site 37
    Surrey, British Columbia V3V0C6, Canada
  • Arcutis Biotherapeutics Clinical Site 47
    Winnepeg, Manitoba R3M 3Z4, Canada
  • Arcutis Biotherapeutics Clinical Site 43
    Fredericton, New Brunswick E3B 1G9, Canada
  • Arcutis Biotherapeutics Clinical Site 38
    Ajax, Ontario L1S 7K8, Canada
  • Arcutis Biotherapeutics Clinical Site 16
    London, Ontario N6H 5L5, Canada
  • Arcutis Biotherapeutics Clinical Site 29
    Mississauga, Ontario L5H 1G9, Canada
  • Arcutis Biotherapeutics Clinical Site 30
    North Bay, Ontario P1B 3Z7, Canada
  • Arcutis Biotherapeutics Clinical Site 32
    Peterborough, Ontario K9J 5K2, Canada
  • Arcutis Biotherapeutics Clinical Site 71
    Toronto, Ontario M4W 2N2, Canada
  • Arcutis Biotherapeutics Clinical Site 36
    Waterloo, Ontario N2J 1C4, Canada
  • Arcutis Biotherapeutics Clinical Site 49
    Windsor, Ontario N8W 1E6, Canada
  • Arcutis Biotherapeutics Clinical Site 09
    Montreal, Quebec H3Z 2S6, Canada
09

References and documents

Publications

  • Gooderham MJ, Alonso-Llamazares J, Bagel J, Bhatia N, Bukhalo M, DuBois J, Ferris LK, Green L, Kircik LH, Lockshin B, Loo WJ, Papp KA, Soung J, Seal MS, Snyder S, Kato S, Krupa D, Burnett P, Berk DR, Chu DH. Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2025 Jul 1;161(7):698-706. doi: 10.1001/jamadermatol.2025.1136. PubMed 40332898 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Jun 2022, 9 months.

Results were first posted in Jul 2025, 3 years 1 month after primary completion. A results delay was requested in Apr 2023.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 31, 2021
StartActual
Aug 24, 2021
Primary completionActual
Jun 3, 2022
CompletionActual
Jun 3, 2022
Results delay requested
Apr 21, 2023
Results first posted
Jul 17, 2025
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05028582
Responsible party
Sponsor
First posted
Aug 31, 2021
Start date
Aug 24, 2021
Primary completion
Jun 3, 2022
Completion
Jun 3, 2022
Results posted
Jul 17, 2025
Last update
Jul 17, 2025

Study contacts

David Berk, MD
study director · Arcutis Biotherapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion